6 Analysts Have This To Say About Corcept Therapeutics
During the last three months, 6 analysts shared their evaluations of Corcept Therapeutics (NASDAQ:CORT), revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 0 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 2 | 0 | 0 | 0 | 0 |
| 2M Ago | 3 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $48.67, a high estimate of $65.00, and a low estimate of $38.00. Surpassing the previous average price target of $45.80, the current average has increased by 6.27%.
Diving into Analyst Ratings: An In-Depth Exploration
The analysis of recent analyst actions sheds light on the perception of Corcept Therapeutics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Joon Lee | Truist Securities | Maintains | Buy | $65.00 | $65.00 |
| Joon Lee | Truist Securities | Raises | Buy | $65.00 | $44.00 |
| Swayampakula Ramakanth | HC Wainwright & Co. | Maintains | Buy | $40.00 | $40.00 |
| Swayampakula Ramakanth | HC Wainwright & Co. | Raises | Buy | $40.00 | $38.00 |
| Joon Lee | Truist Securities | Raises | Buy | $44.00 | $42.00 |
| Swayampakula Ramakanth | HC Wainwright & Co. | Maintains | Buy | $38.00 | - |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Corcept Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Corcept Therapeutics compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for Corcept Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
To gain a panoramic view of Corcept Therapeutics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Corcept Therapeutics analyst ratings.
Discovering Corcept Therapeutics: A Closer Look
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
Corcept Therapeutics: Delving into Financials
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Corcept Therapeutics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 38.95% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 18.74%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Corcept Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.22% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Corcept Therapeutics's ROA excels beyond industry benchmarks, reaching 4.31%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.0.
The Core of Analyst Ratings: What Every Investor Should Know
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.